Noa Therapeutics received National Eczema Association Awards Grant to work with Johns Hopkins​

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Noa Therapeutics, a Toronto-based biotechnology company pioneering a biased engagement approach to the aryl hydrocarbon receptor (AhR), a master regulator of immunity, recently announced that the Johns Hopkins University (JHU) Department of Dermatology has been awarded a prestigious Catalyst Research Grant from the National Eczema Association (NEA) to study Noa's lead drug compound in preclinical models of atopic dermatitis.

Noa Therapeutics is an OBIO® member, alumnus of our BDSP™, CAAP®, H2BB™ and WiHI programs, and presented at the OBIO® Investment Summit.

Read more
Arsheen Kaur
Previous

Health Canada gives green light to new study investigating novel made-in-Canada drug candidate to prevent brain injury in hemodialysis patients
Next

Durham Ontario Health Team (OHT) and Community Care Durham (CCD) Partner with Health Espresso to Launch Innovative Community Engagement Tool with Support from OBIO®